Linking insertional mutagenesis and cell function to improve CAR T cell therapy

将插入突变与细胞功能联系起来以改善 CAR T 细胞疗法

• 批准号: 10640072
• 负责人: Frederic D Bushman
• 金额: $ 59.21万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-06-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10640072
• 关键词: Acute Lymphocytic Leukemia; Adult Acute Lymphocytic Leukemia; Alleles; Animal Model; Antigens; Apoptosis; Automobile Driving; B lymphoid malignancy; Bioinformatics; Biological Assay; CAR T cell therapy; CD19 gene; Cancer Patient; Cell Culture Techniques; Cell physiology; Cells; Cessation of life; Childhood Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Clinical; Clonal Expansion; Clone Cells; Clustered Regularly Interspaced Short Palindromic Repeats; Custom; Cyclic AMP; DNA; Data; Data Set; Disease remission; Engineering; Enzymes; Event; Failure; Gene Modified; Gene Targeting; Genes; Genome; Goals; Hand; Human; Human Genome; Inositol Phosphates; Insertional Mutagenesis; Lentivirus Vector; Link; Malignant Neoplasms; Methods; Multiple Myeloma; Mutagens; Output; Pathway interactions; Patients; Phosphotransferases; Positioning Attribute; Proliferating; Proteins; Publishing; Reagent; Reporter Genes; Reporting; Role; Route; Sampling; Series; Solid Neoplasm; Specific qualifier value; System; T cell differentiation; T cell therapy; T-Cell Proliferation; T-Lymphocyte; TGFBR2 gene; Testing; Therapeutic; Time; Translating; Tumor Antigens; Validation; cancer cell; cancer immunotherapy; cancer therapy; cell growth; chimeric antigen receptor; clinical development; cohort; deep sequencing; demethylation; engineered T cells; follow-up; gene function; genetic manipulation; high risk; improved; improved outcome; integration site; kinase inhibitor; lentiviral integration; leukemia; longitudinal analysis; mouse model; personalized cancer therapy; receptor; relapse risk; response; success; tissue culture; tumor; vector

Summary Chimeric antigen receptor-engineered T cells (CAR T cells) provide a breakthrough for personalized cancer therapy. In this approach, a gene encoding a CAR targeting tumor antigens is delivered into patient T-cells ex vivo using a lentiviral vector, then cells reinfused into patients. The engineered CAR T cells expand in the patient and attack and destroy tumor antigen-positive cancer cells. Robust clinical responses are seen with CAR T cell therapy in some leukemias such as pediatric acute lymphocytic leukemia (ALL), but lower rates of response in adult ALL, chronic lymphocytic leukemia (CLL) and multiple myeloma. One consequence of integration of a CAR- encoding lentiviral vector in patient T cells is local disruption of the host genome. We recently published an example where the resulting insertional mutagenesis bolstered successful therapy--patient T-cell expansion was associated with an integration event in TET2, which encodes an enzyme involved in CpG demethylation, and this was mechanistically linked with enhanced T cell function and durable remission. Here we take advantage of data from insertional mutagenesis of patient CAR T cells to identify genes and pathways of particular importance for effective anti-tumor activity. TGFBR2 provides a second example of where insertional mutagenesis was associated with expansion of CAR T cells, and separate studies have also implicated reduced function of this gene as associated with improved CART function. Intense efforts are now under way to modulate both of these pathways to enhance therapeutic success. We have completed longitudinal analysis of integration site distributions in 40 CAR T-treated subjects, targeting both ALL and CLL, and find numerous examples of clonal expansions in patients successfully responding to therapy, providing a unique window on CAR T cell function. We have in hand samples from another 266 subjects, some of whom are responders showing long term persistence of CAR T cells. We have further devised a series of assays in cell culture and mouse models to modulate activity of targeted genes and characterize CAR T cell proliferation and anti-tumor activity. Thus we propose to investigate these genes and pathways in detail and develop means for manipulating them clinically. We propose the following Specific Aims: Aim 1. Elucidate the rules governing superior CAR T cell proliferation and persistence taking advantage of lentiviral integration as an insertional mutagen. Aim 2. Carry out functional analyses of genes implicated in vector driving of CAR T cells to identify proteins and pathways important for CAR T proliferation, persistence and anti-tumor activity. The output of this project will be methods for manipulating genes and pathways important for effective CAR T proliferation and function, which will then be taken directly into clinical development.

总结 嵌合抗原受体工程化T细胞（CAR T细胞）为个性化癌症提供了突破 疗法在这种方法中，编码靶向肿瘤抗原的CAR的基因被递送到患者T细胞中， 体内使用慢病毒载体，然后将细胞重新输注到患者体内。工程化CAR T细胞在患者体内扩增 攻击并摧毁肿瘤抗原阳性癌细胞。使用CAR T细胞观察到稳健的临床应答 治疗某些白血病，如小儿急性淋巴细胞白血病（ALL），但反应率较低， 成人ALL、慢性淋巴细胞白血病（CLL）和多发性骨髓瘤。整合CAR的一个结果- 在患者T细胞中的编码慢病毒载体是宿主基因组的局部破坏。我们最近发布了一份 由此产生的插入诱变支持成功治疗的实例-患者T细胞扩增被 与TET 2中的整合事件相关，TET 2编码参与CpG去甲基化的酶，和 这在机制上与T细胞功能增强和持久缓解有关。在这里，我们利用 来自患者CAR T细胞的插入诱变的数据，以鉴定特别重要的基因和途径 有效的抗肿瘤活性。TGFBR 2提供了插入诱变的第二个例子。 与CAR T细胞的扩增相关，并且单独的研究也暗示了这种功能的降低。 与改善的CART功能相关的基因。目前正在加紧努力调整这两个方面 提高治疗成功率的途径。我们已经完成了整合位点的纵向分析 在40名CAR T治疗的受试者中，靶向ALL和CLL，并发现了许多克隆的例子。 成功对治疗产生反应的患者的扩增，为CAR T细胞功能提供了独特的窗口。 我们手头有来自另外266名受试者的样本，其中一些人是反应者， CAR T细胞的持久性。我们进一步设计了一系列细胞培养和小鼠模型的试验， 调节靶基因的活性并表征CAR T细胞增殖和抗肿瘤活性。因此我们 我们建议详细研究这些基因和途径，并开发出在临床上操纵它们的方法。 我们提出以下具体目标：目标1。阐明控制上级CAR T细胞增殖的规则 以及利用慢病毒整合作为插入诱变剂的持久性。目标2.进行功能 分析与CAR T细胞的载体驱动有关的基因，以鉴定对CAR重要的蛋白质和途径 T细胞增殖、持久性和抗肿瘤活性。该项目的输出将是用于操作 对于有效的CAR T增殖和功能重要的基因和途径，然后将直接 进入临床开发。